Wu Wei, Dong Ming-Qing, Wu Xing-Gang, Sun Hai-Ying, Tse Hung-Fat, Lau Chu-Pak, Li Gui-Rong
Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
Biochim Biophys Acta. 2012 Feb;1823(2):282-9. doi: 10.1016/j.bbamcr.2011.10.010. Epub 2011 Oct 28.
Human ether á-go-go gene potassium channels (hEAG1 or Kv10.1) are expressed in brain and various human cancers and play a role in neuronal excitement and tumor progression. However, the functional regulation of hEAG channels by signal transduction is not fully understood. The present study was therefore designed to investigate whether hEAG1 channels are regulated by protein tyrosine kinases (PTKs) in HEK 293 cells stably expressing hEAG1 gene using whole-cell patch voltage-clamp, immunoprecipitation, Western blot, and mutagenesis approaches. We found that the selective epidermal growth factor receptor (EGFR) kinase inhibitor AG556 (10 μM), but not the platelet growth factor receptor (PDGFR) kinase inhibitor AG1295 (10 μM) or the Src-family inhibitor PP2 (10 μM), can inhibit hEAG1 current, and the inhibitory effect can be reversed by the protein tyrosine phosphatase (PTP) inhibitor orthovanadate. Immunoprecipitation and Western blot analysis revealed that tyrosine phosphorylation level of hEAG1 channels was reduced by AG556, and the reduction was significantly countered by orthovanadate. The hEAG1 mutants Y90A, Y344A and Y485A, but not Y376A and Y479A, exhibited reduced response to AG556. Interestingly, the inhibition effect of AG556 was lost in triple mutant hEAG1 channels at Y90, Y344, and Y485 with alanine. These results demonstrate for the first time that hEAG1 channel activity is regulated by EGFR kinase at the tyrosine residues Tyr90, Try344, and Try485. This effect is likely involved in regulating neuronal activity and/or tumor growth.
人类醚 - 去极化基因钾通道(hEAG1或Kv10.1)在大脑和多种人类癌症中表达,并在神经元兴奋和肿瘤进展中发挥作用。然而,信号转导对hEAG通道的功能调节尚未完全了解。因此,本研究旨在使用全细胞膜片电压钳、免疫沉淀、蛋白质印迹和诱变方法,研究在稳定表达hEAG1基因的HEK 293细胞中,hEAG1通道是否受蛋白酪氨酸激酶(PTK)调节。我们发现,选择性表皮生长因子受体(EGFR)激酶抑制剂AG556(10 μM)可抑制hEAG1电流,而血小板生长因子受体(PDGFR)激酶抑制剂AG1295(10 μM)或Src家族抑制剂PP2(10 μM)则不能,并且该抑制作用可被蛋白酪氨酸磷酸酶(PTP)抑制剂原钒酸盐逆转。免疫沉淀和蛋白质印迹分析显示,AG556可降低hEAG1通道的酪氨酸磷酸化水平,而原钒酸盐可显著对抗这种降低。hEAG1突变体Y90A、Y344A和Y485A对AG556的反应降低,而Y376A和Y479A则没有。有趣的是,在Y90、Y344和Y485位点被丙氨酸取代的三联体突变hEAG1通道中,AG556的抑制作用消失。这些结果首次证明,hEAG1通道活性在酪氨酸残基Tyr90、Try344和Try485处受EGFR激酶调节。这种作用可能参与调节神经元活动和/或肿瘤生长。